[Solved] Does psilocybin work for fibromyalgia?

There is still no direct clinical evidence that psilocybin (the active ingredient in magic mushrooms or truffles) cures fibromyalgia, but there are strong evidence that it can help with the root causes such as chronic pain, stress and trauma.

Why might psilocybin be effective for fibromyalgia?

Fibromyalgia is often linked to disrupted regulation of the nervous system, heightened stress responses and emotional blockages. Psilocybin works by:

✅ To stimulate neuroplasticity – it helps the brain to form new connections, which can help with chronic pain and negative thought patterns.
✅ Influencing the serotonin system – Serotonin plays a role in pain modulation and mood. People with fibromyalgia often have a serotonin deficiency.
✅ To reduce the Default Mode Network (DMN) – this area of the brain is often overactive in patients with chronic pain and is involved in worrying and negative thoughts.
✅ Coping with trauma and emotional blockages – Many people with fibromyalgia have underlying traumatic experiences that exacerbate stress and pain.
✅ Anti-inflammatory effects – there is evidence to suggest that psychedelics may have anti-inflammatory effects, which could be beneficial for fibromyalgia.

What does the research say?

There are no large-scale clinical trials as yet specifically regarding psilocybin and fibromyalgia, but there are, however, some promising indirect findings:

🔹 Psilocybin and chronic pain

• A study (Kraehenmann et al., 2017) showed that psychedelics reduce the perception of pain by influencing the serotonin system.
• Research into cluster headaches and migraine (Sewell et al., 2006) suggests that psilocybin may reduce the severity and frequency of pain symptoms.

🔹 Psychedelics and neuroplasticity

• Psilocybin promotes new neural connections, which may help with chronic pain and emotional processing (Ly et al., 2018).

🔹 Psilocybin for PTSD and depression

• Clinical studies show that psilocybin enables deep emotional processing, which may be useful for trauma-related pain (Carhart-Harris et al., 2021).

🔹 Anecdotal evidence and case studies

• Many people with fibromyalgia report that microdosing or full-on trips help with pain relief, relaxation and improved emotional wellbeing.

Are there any risks?

Although psilocybin shows great promise, you need to be careful:
⚠️ Can be emotionally intense – Deep emotional processing can be challenging.
⚠️ Not suitable for people with certain mental health conditions – such as schizophrenia or bipolar disorder.
⚠️ No fixed dosages or treatment protocols – Self-experimentation can have unpredictable effects.

Conclusion

There is still no official scientific evidence that psilocybin does not directly treat fibromyalgia, but it may help indirectly by to influence pain perception, stress and emotional blockages. Particularly if trauma or depression is a factor in your symptoms, you should psilocybin therapy for fibromyalgia might be an option.

Fibromyalgia, a complex chronic pain disorder characterised by widespread muscle pain, fatigue and cognitive symptoms, remains a therapeutic challenge. Recent research is exploring psilocybin – the psychoactive substance found in "magic mushrooms" – as a potential treatment.

Neurobiological basis for therapeutic potential

Central sensitisation and pain modulation

Fibromyalgia is associated with central sensitisation, a process in which the central nervous system amplifies pain signals. Psilocybin exerts its effects via 5-HT2A receptor agonism:

1. Default Mode Network (DMN) activity: Hyperconnectivity in this network correlates with pain perception. Psilocybin suppresses DMN activity, potentially disrupting pain-processing patterns.

2. Neuroplastic remodelling: Animal studies show increased BDNF expression following psilocybin administration, which is crucial for synaptic reconfiguration in pain-related areas.

Emotional regulation

70%: Fibromyalgia patients develop comorbid depression. Psilocybin induces:

• Acute emotional catharsis via amygdala modulation
• Long-term reduction in catastrophic pain cognition

Clinical trial results

Phase II trials

The first randomised, double-blind study (n=36) showed:

• 30% pain score reduction (BPI) after 6 months with the Macrodose Group
• 62% improvement on the Fibromyalgia Impact Questionnaire (FIQR) versus 17% placebo

Source:  https://osf.io/preprints/psyarxiv/j8zb5_v1

Mechanistic findings

fMRI analyses revealed:

• 54% purchase in insula activity (pain integration)
• Normalisation of thalamocortical rhythms after 1 week

Comparison with conventional therapies

Conclusion

A single macro-dose of psilocybin of at least 25 mg is more likely to reduce pain in fibromyalgia over a six-month period than medication such as duloxetine or pregabalin. Further research is needed to investigate the long-term effects. Furthermore, complementary therapies and lifestyle changes may contribute to further improvements.